MicroCHIPS was founded in 1999 as an MIT spinoff to develop implantable sensors and drug-delivery devices.
MicroCHIPS’ drug-delivery technology is based on proprietary reservoir arrays that are used to store potent drugs within the body for long periods of time. Individual device reservoirs can be opened on demand or on a predetermined schedule to precisely control drug release or sensor activation.
MicroCHIPS’ current drug delivery efforts are focused on the development and testing of a delivery device for PTH(1-34) for the treatment of osteoporosis. For the 200 million people world-wide with osteoporosis, poor compliance with daily injections of anabolic agents limits their effectiveness. MicroCHIPS’ delivery device under development has the potential to overcome the compliance limitations associated with injectable drug delivery.
In February 2011, MicroCHIPS announced the start of its clinical trial to assess the pharmacokinetics of long-term parathyroid hormone (hPTH 1-34) delivery in women with osteoporosis.
Company website: http://mchips.com
Click here for MicroCHIPS’ patents.